CSL Limited (CSLLY)
(Delayed Data from OTC)
$86.51 USD
-1.11 (-1.26%)
Updated Aug 7, 2025 11:15 AM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CSLLY 86.51 -1.11(-1.26%)
Will CSLLY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CSLLY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CSLLY
ALKS or CSLLY: Which Is the Better Value Stock Right Now?
KMDA vs. CSLLY: Which Stock Should Value Investors Buy Now?
CSLLY: What are Zacks experts saying now?
Zacks Private Portfolio Services
BMRN vs. CSLLY: Which Stock Is the Better Value Option?
BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?
BMRN or CSLLY: Which Is the Better Value Stock Right Now?
Other News for CSLLY
U.S. to phase out funding for mRNA vaccine development
RFK Jr. formally orders removal of thimerosal from all flu vaccines
CSL Ltd Reorganizes R&D, Plans Workforce Reduction
CSL will reduce its R&D department, increase external alliances: Reuters
Why Vertex Pharmaceuticals Continues To Outperfrom